FDA Plans AdCom Meeting on Vascepa, Pushing CVD Approval

Share this post

Vascepa, a high-dose purified form of eicosapentaenoic acid, showed significant benefit on CV events in the REDUCE-IT study, but any approval date for this indication will now be extended.
Medscape Medical News

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Share this post

Be the first to comment

Leave a Reply